Denmark to reconsider exclusion of J&J and AstraZeneca shots
Reuters
Published May 31, 2021 17:54
COPENHAGEN (Reuters) - Denmark's government on Monday asked the country's health authorities to reconsider a decision to exclude Johnson & Johnson (NYSE:JNJ)'s and AstraZeneca's (L:AZN) COVID-19 shots from its vaccination programme.
The move was prompted by a two-week delay in the Danish vaccination programme to September due to delivery of fewer Moderna (NASDAQ:MRNA) and CureVac vaccines than expected, Health Minister Magnus Heunicke said.
Denmark excluded the J&J and AstraZeneca vaccines over a potential link to a rare but serious form of blood clot.
"We are now further into the epidemic, and the vaccines from Johnson & Johnson and AstraZeneca have now been in use in Europe for some time, Heunicke said.
"There is a larger data base worldwide to assess the effect and side effects of the vaccines," he said.
The health authority found in early May that the benefits of using the COVID-19 vaccines did not outweigh the risk of causing the possible adverse effect in those who receive the vaccine.
Excluding the J&J vaccine, which accounts for around a third of Denmark's total contracted supplies of COVID-19 shots, delayed the country's vaccination calendar by up to four weeks, the health authority said.
Denmark had vaccinated 21% of its population as of Monday.
Get The App
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.